123 related articles for article (PubMed ID: 3991370)
1. Tissue polypeptide antigen (TPA) as a prognostic aid in human prostatic carcinoma.
Lewenhaupt A; Ekman P; Eneroth P; Nilsson B; Nordström L
Prostate; 1985; 6(3):285-91. PubMed ID: 3991370
[TBL] [Abstract][Full Text] [Related]
2. Serum tissue polypeptide antigen (TPA) and prostatic acid phosphatase (PAP) in patients with prostatic cancer.
Marczyńska A; Kulpa J; Leńko J; Augustyn M
Int Urol Nephrol; 1988; 20(2):123-9. PubMed ID: 2454895
[TBL] [Abstract][Full Text] [Related]
3. Tissue polypeptide antigen (TPA) and prostatic acid phosphatase in serum of prostatic cancer patients.
Huber PR; Rist M; Hering F; Biedermann C; Rutishauser G
Urol Res; 1983; 11(5):223-6. PubMed ID: 6659214
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical prostatic acid phosphatase level as a prognostic factor of prostatic carcinoma.
Sakai H; Shiraishi K; Minami Y; Yushita Y; Kanetake H; Saito Y
Prostate; 1991; 19(3):265-72. PubMed ID: 1946042
[TBL] [Abstract][Full Text] [Related]
5. [Prognostic value of prostatic acid phosphatase in stage B and C prostatic cancer. Apropos of 84 cases].
Guerin JL; Canal P; Douchez J; Soula G
Bull Cancer; 1989; 76(10):1077-82. PubMed ID: 2635635
[TBL] [Abstract][Full Text] [Related]
6. [Tissue polypeptide antigen as a marker for prostatic neoplasms. Preliminary study].
Ruibal A; Durán P; Ibarz L; Fraile M; Roca I; de Torres Mateos JA
Arch Esp Urol; 1984; 37(5):399-403. PubMed ID: 6517625
[No Abstract] [Full Text] [Related]
7. Serum levels of prostatic acid phosphatase (PAP), tissue polypeptide antigen (TPA), CA-50, neopterine and of osteocalcin in patients with prostatic carcinoma.
Lewenhaupt A; Ekman P; Eneroth P; Eriksson A; Nordström L
Scand J Clin Lab Invest Suppl; 1985; 179():75-80. PubMed ID: 3878574
[No Abstract] [Full Text] [Related]
8. Tissue polypeptide antigen expression in human prostate tumors.
Ghazizadeh M; Kagawa S; Oguro T; Takigawa H; Sasaki Y; Aihara K
J Cancer Res Clin Oncol; 1989; 115(1):84-8. PubMed ID: 2466035
[TBL] [Abstract][Full Text] [Related]
9. Serum TPS, PSA, and PAP values in relapsing stage D2 adenocarcinoma of the prostate.
Kraljić I; Kovacić K; Tarle M
Urol Res; 1994; 22(5):329-32. PubMed ID: 7533445
[TBL] [Abstract][Full Text] [Related]
10. [The clinical significance of serum tissue polypeptide antigen as a tumor marker for urogenital carcinomas--a comparison with other tumor markers in patients with renal cell carcinoma and prostatic carcinoma].
Yamazaki K; Kumamoto Y; Tsukamoto T; Umehara T; Ohmura K
Hinyokika Kiyo; 1987 Oct; 33(10):1581-9. PubMed ID: 2451408
[TBL] [Abstract][Full Text] [Related]
11. Prostate-specific antigen as a marker of adenocarcinoma of prostate.
Kellokumpu-Lehtinen P; Nurmi M; Koskinen P; Irjala K
Urol Res; 1989; 17(4):245-9. PubMed ID: 2475959
[TBL] [Abstract][Full Text] [Related]
12. Tissue concentrations of tissue polypeptide antigen (TPA) and prostatic specific antigen (PSA) in 42 patients with prostatic carcinoma.
Grande M; Carlström K; Lundh Rozell B; Eneroth P; Stege R; Pousette A
Prostate; 2000 Dec; 45(4):299-303. PubMed ID: 11102954
[TBL] [Abstract][Full Text] [Related]
13. Comparative analysis of fluctuation of serum tumor markers in advanced cancer of prostate.
Maatman TJ
Urology; 1993 Dec; 42(6):672-6. PubMed ID: 7504849
[TBL] [Abstract][Full Text] [Related]
14. [Clinical studies on tumor markers for monitoring prostate cancer patients; the evaluation of prostate-specific antigen and comparison with prostatic acid phosphatase and gamma-seminoprotein].
Shinoda I
Nihon Gan Chiryo Gakkai Shi; 1990 Nov; 25(11):2627-39. PubMed ID: 1703555
[TBL] [Abstract][Full Text] [Related]
15. The contemporary value of pretreatment prostatic acid phosphatase to predict pathological stage and recurrence in radical prostatectomy cases.
Moul JW; Connelly RR; Perahia B; McLeod DG
J Urol; 1998 Mar; 159(3):935-40. PubMed ID: 9474187
[TBL] [Abstract][Full Text] [Related]
16. [Prostate-specific antigen. A new biological serum marker for prostatic adenocarcinoma].
Haukaas S; Skaarland E; Halvorsen OJ; Stensland E; Farstad M
Tidsskr Nor Laegeforen; 1990 Sep; 110(23):2990-3. PubMed ID: 1700496
[TBL] [Abstract][Full Text] [Related]
17. Serial measurements of tissue polypeptide specific antigen (TPS), PSA, PAP and CEA serotest values in treated patients with primary and metastatic prostate cancer.
Tarle M
Anticancer Res; 1993; 13(3):769-77. PubMed ID: 7686362
[TBL] [Abstract][Full Text] [Related]
18. Correlation of cell proliferation marker (TPS), natural killer (NK) activity and tumor load serotest (PSA) in untreated and treated prostatic tumors.
Tarle M; Kovacić K; Kastelan M
Anticancer Res; 1993; 13(1):215-8. PubMed ID: 7682800
[TBL] [Abstract][Full Text] [Related]
19. [The value of the serum level of the prostate-specific antigen in prostatic pathology].
Théodon P; Rymer JC; Chopin D; Kouyoudjian JC; Abbou CC; Auvert J
Ann Urol (Paris); 1988; 22(3):199-205. PubMed ID: 2456713
[TBL] [Abstract][Full Text] [Related]
20. The relation of prostatic acid phosphatase and prostate specific antigen with tumour grade in prostatic adenocarcinoma: an immunohistochemical study.
Ersev A; Ersev D; Turkeri L; Ilker Y; Simsek F; Kullu S; Akdas A
Prog Clin Biol Res; 1990; 357():129-34. PubMed ID: 1699237
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
